Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL
Although the tyrosine kinase inhibitor imatinib has been shown to be an active agent in patients with gastrointestinal stromal tumours (GIST), complete remissions are almost never seen and most patients finally experience disease progression during their course of treatment. An alternative therapeut...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584951/ https://www.ncbi.nlm.nih.gov/pubmed/18941456 http://dx.doi.org/10.1038/sj.bjc.6604736 |